Resumen:
Alginate is a biomaterial that has demonstrated considerable potential and adaptability in the field of controlled drug delivery due to its unique physicochemical properties. Chemical modification of alginate has significantly enhanced its functionality, allowing the development of matrices with improved characteristics, such as increased affinity
for hydrophobic drugs, sustained and controlled release, and improved cell and tissue adhesion. Hydrogels, microspheres, nanoparticles, and porous scaffolds are among the most extensively studied alginate-based drug delivery systems. It is estimated that over 50% of these systems have shown successful outcomes in in vitro testing, particularly
in applications such as oral delivery of proteins and peptides, wound healing, tissue regeneration, and cancer therapy. Recent clinical advances involving alginate include the development of wound dressings, growth factor delivery systems, and cell based therapies for treating degenerative diseases. Chemically modified alginate thus emerges as a highly
adaptable and promising candidate for the design of advanced drug delivery systems across a wide range of biomedical applications. This review encompasses more than
100 research articles and aims to provide an updated overview of the current state of knowledge regarding the use of chemically modified alginate-based hydrogel systems in
drug delivery.
Descripción:
This review highlights the relevance of chemically modified alginate-based hydrogel matrices in drug delivery and their potential applications in various medical treatments, including cancer, diabetes, tissue regeneration scaffolds, and wound healing. Special attention is given to the diverse chemical modification methods used to enhance the functionality
of alginate and increase its suitability for biomedical applications. Despite their promise, the large-scale deployment of modified hydrogels faces several challenges.
Key issues include environmental impact, cost, and the complexities of regulatory approval and legal frameworks. Regulatory processes, particularly in the United States, can be
especially intricate. Agencies such as the FDA frequently categorize these systems as medical “devices”, and when intended for pharmacological or cell-based therapies, they
are defined as “combination products”. As a result, these technologies must undergo the Premarket Notification process, which may span up to a decade, significantly delaying their
entry into clinical use and hindering commercial viability. Overcoming these regulatory barriers requires advocacy beyond the research community, especially when safety, efficacy, and biocompatibility have already been validated. Additionally, scaling up production demands careful consideration of multiple factors, including the availability and cost of raw materials, environmental sustainability of modification methods, nature of byproducts
generated, product shelf life, and usability in clinical settings. Looking forward, personalized medicine offers a promising direction for further development. The ultimate goal
is to engineer hydrogel biomaterials tailored to the unique therapeutic requirements of individual patients. The next major breakthrough in biomaterials engineering is anticipated
to involve the design of hydrogels capable of delivering precise, patient-specific therapeutic solutions.